A Phase 1 interventional study of PF-07799933 and binimetinib in Melanoma, Non-Small-Cell Lung Cancer and Thyroid Cancer, sponsored by Pfizer. Active, not recruiting at 40 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.
Among the 52 studies in Melanoma by Pfizer, this one is the 18th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2022, is one of 27 in phase 1, and was the 40th registered.
3,374 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Netherlands and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 19 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 77 across the 48 interventional studies, 496 across the 2 observational. Of the 47 that completed or were terminated, 23 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Melanoma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Melanoma by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer.
All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine:
Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
This study is seeking participants who meet the following key eligibility criteria:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive PF-07799933
Drug: PF-07799933
Participants will receive PF-07799933 in combination with binimetinib or cetuximab
Drug: PF-07799933 · Drug: binimetinib · Biological: cetuximab
Participants will receive PF-07799933
Drug: PF-07799933
Participants will receive PF-07799933
Drug: PF-07799933 · Drug: binimetinib
Participants will receive PF-07799933
Drug: PF-07799933 · Drug: midazolam
Participants will receive PF-07799933 in combination with cetuximab
Drug: PF-07799933 · Biological: cetuximab
Participants will receive PF-07799933 in combination with cetuximab and mFOLFOX6 regimen
Drug: PF-07799933 · Biological: cetuximab · Drug: fluorouracil · Drug: leucovorin · Drug: oxaliplatin
Participants will receive PF-07799933
Drug: PF-07799933
Participants will receive PF-07799933
Drug: PF-07799933
Tablet
Also known as: ARRY-440
Tablet
Also known as: Mektovi, PF-06811462, MEK162
Injection for intravenous use
Also known as: Erbitux
syrup
Injection for intravenous use
Injection for intravenous use
Injection for intravenous use
Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2)
DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib or cetuximab
Time frame: Cycle 1 (21 days)
Number of participants with treatment-emergent adverse events (AEs) (Part 1 and Part 2)
AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy
Time frame: Baseline to 28 days after last dose of study medication
Number of participants with clinically significant change from baseline in laboratory abnormalities (Part 1 and Part 2)
Laboratory abnormalities as characterized by type, frequency, severity, and timing
Time frame: Baseline to 28 days after last dose of study treatment
Number of participants with clinically significant change from baseline in vital sign abnormalities (Part 1 and Part 2)
Vital sign abnormalities as characterized by type, frequency, severity, and timing
Time frame: Baseline to 28 days after last dose of study treatment
Dose interruptions due to AEs (Part 1 and Part 2)
Incidence of dose interruptions due to AEs
Time frame: Baseline to 2 years
Dose dose modifications due to AEs (Part 1 and Part 2)
Incidence of dose modifications due to AEs
Time frame: Baseline to 2 years
Discontinuations due to AEs (Part 1 and Part 2)
Incidence of discontinuations due to AEs
Time frame: Baseline to 2 years
Overall response rate (ORR) (Part 3)
Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Time frame: Baseline to 2 years
Number of participants with clinically significant physical exam abnormalities (Part 1 and Part 2)
Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: Baseline to 28 days after last dose of study treatment
Part 1 and Part 2: ORR
ORR as assessed using the RECIST version 1.1.
Time frame: Baseline to 2 years
Part 1/2/3: Intracranial response
Intracranial response by RECIST version 1.1 (for brain metastases) \& Response Assessment in Neuro-Oncology (RANO) - for primary brain tumors).
Time frame: Baseline to 2 years
Part 1 and Part 2: Duration of response
Duration of response
Time frame: Baseline to 2 years
Part 3: Number of participants with treatment-emergent adverse events (AEs)
AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy
Time frame: Baseline to 2 years
Part 3: Number of participants with clinically significant change from baseline in laboratory abnormalities
Laboratory abnormalities as characterized by type, frequency, severity, and timing
Time frame: Baseline to 2 years
Part 3: Number of participants with clinically significant change from baseline in vital sign abnormalities
Vital sign abnormalities as characterized by type, frequency, severity, and timing
Time frame: Baseline to 2 years
Part 3: Dose interruptions due to AEs
Incidence of dose interruptions due to AEs
Time frame: Baseline to 2 years
Part 3: Dose dose modifications due to AEs
Incidence of dose modifications due to AEs
Time frame: Baseline to 2 years
Part 3: Discontinuations due to AEs
Incidence of discontinuations due to AEs
Time frame: Baseline to 2 years
Part 3: Time to event endpoints in each combination
Time to event endpoints in each combination
Time frame: Baseline to 2 years
Part 3: Disease Control Rate (DCR)
DCR
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, maximum observed concentration (Cmax)
PK parameters of PF-07799933, Single dose, Cmax
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, time to maximum plasma concentration (Tmax)
PK parameters of PF-07799933, Single dose, Tmax
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast)
PK parameters of PF-07799933, Single dose, AUClast
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, area under plasma concentration-time curve over 24 hours (AUC24)
PK parameters of PF-07799933, Single dose, AUC24
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, area under plasma concentration-time curve over 48 hours (AUC48)
PK parameters of PF-07799933, Single dose, AUC48
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, terminal elimination half life (t½)
PK parameters of PF-07799933, Single dose, t½
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf)
PK parameters of PF-07799933, Single dose, AUCinf
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, apparent oral clearance (CL/F)
PK parameters of PF-07799933, Single dose, CL/F
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Single dose, apparent volume of distribution (Vz/F)
PK parameters of PF-07799933, Single dose, Vz/F
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, maximum observed concentration (Cmax)
PK parameters of PF-07799933, Multiple dose, Cmax
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, trough plasma or serum concentration (Ctrough)
PK parameters of PF-07799933, Multiple dose, Ctrough
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, time to maximum plasma concentration (Tmax)
PK parameters of PF-07799933, Multiple dose, Tmax
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, area under the plasma concentration-time curve over the dosing interval (AUCτ)
PK parameters of PF-07799933, Multiple dose, AUCτ
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, CL/F
PK parameters of PF-07799933, Multiple dose, CL/F
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, average plasma concentration (Cav)
PK parameters of PF-07799933, Multiple dose, Cav
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, peak-to-trough ratio (PTR)
PK parameters of PF-07799933, Multiple dose, PTR
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, accumulation ratio (Rac)
PK parameters of PF-07799933, Multiple dose, Rac (AUCτ /AUCsd,τ)
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, t1/2
PK parameters of PF-07799933, Multiple dose, t1/2
Time frame: Baseline to 2 years
Part 1/2/3: PK parameters of PF-07799933, Multiple dose, Vz/F
PK parameters of PF-07799933, Multiple dose, Vz/F
Time frame: Baseline to 2 years
Part 3: PK parameters of cytochrome P450 (CYP)3A4 probe substrate midazolam, Cmax
PK parameters of CYP3A4 probe substrate midazolam, Cmax
Time frame: Baseline to 2 years
Part 3: PK parameters of CYP3A4 probe substrate midazolam, Tmax
PK parameters of CYP3A4 probe substrate midazolam, Tmax
Time frame: Baseline to 2 years
Part 3: PK parameters of CYP3A4 probe substrate midazolam, AUClast
PK parameters of CYP3A4 probe substrate midazolam, AUClast
Time frame: Baseline to 2 years
Part 3: PK parameters of CYP3A4 probe substrate midazolam, t½
PK parameters of CYP3A4 probe substrate midazolam, t½
Time frame: Baseline to 2 years
Part 3: PK parameters of CYP3A4 probe substrate midazolam, AUCinf
PK parameters of CYP3A4 probe substrate midazolam, AUCinf
Time frame: Baseline to 2 years
Part 3: PK parameters of CYP3A4 probe substrate midazolam, CL/F
PK parameters of CYP3A4 probe substrate midazolam, CL/F
Time frame: Baseline to 2 years
Part 3: PK parameters of CYP3A4 probe substrate midazolam, Vz/F
PK parameters of CYP3A4 probe substrate midazolam, Vz/F
Time frame: Baseline to 2 years
Part 3: TTR
Time to response (TTR)
Time frame: Baseline to 2 years
Part 3: DOR
Duration of response (DOR)
Time frame: Baseline to 2 years
Part 3: PFS
Progression-free survival (PFS)
Time frame: Baseline to 2 years
Part 3: OS
Overall survival (OS)
Time frame: Baseline to 2 years
Number of participants with clinically significant physical exam abnormalities (Part 3)
Physical exam abnormalities as as graded by NCI CTCAE version 5.0
Time frame: Baseline to 28 days after last dose of study medication
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 61 months after the start.
Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 61 months is above that.
Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.